Voyager Therapeutics Stock News

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

Voyager Digital had 3.5 million customers, and many are now doing everything they can to try and get some of their money back.

Court proceedings and financial documents detail how complicated relationships were between the two Bankman-Fried firms — Alameda and FTX — and Voyager Digital.

Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Julie Burek - Vice President of Finance Dr. Al Sandrock - Chief Financial Offic

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau

Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.15% and 5.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-ass

Alnylam (ALNY) delivered earnings and revenue surprises of -41.36% and 13.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (

VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing

Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis

Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.